Global Enoxaparin Sodium Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Enoxaparin Sodium Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Enoxaparin sodium is an anticoagulant medication (blood thinner).It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) including during pregnancy and following certain types of surgery. It is also used in those with acute coronary syndrome (ACS) and heart attacks. It is given by injection just under the skin or into a vein.It is also used during hemodialysis.
Enoxaparin Sodium report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Enoxaparin Sodium market is projected to reach US$ 5354.7 million in 2034, increasing from US$ 3044.5 million in 2022, with the CAGR of 8.3% during the period of 2024 to 2034. Demand from Hospital and Clinic are the major drivers for the industry.
Europe is the largest market of Enoxaparin Sodium, with about 60% market share, followed by North America with about 17% market share. Currently, there are many players in this market.Sanofi, Teva, Techdow (Hepalink), Fresenius Kabi, Rovi, Amphastar, Nanjing King-friend, Sandoz and some others are playing important roles in Enoxaparin sodium injection industry. Sanofi, Teva, Techdow (Hepalink), Fresenius Kabi and Rovi are the top 5 players of Enoxaparin Sodium, with about 85% market shares.
There are nine different dosage form of Enoxaparin Sodium. The market can be segmented into 20 mg/0.2mL, 30 mg/0.3mL, 40 mg/0.4mL, 60 mg/0.6mL, 80 mg/0.8mL, 100 mg/1mL, 120 mg/0.8mL, 150 mg/1mL, 300mg/3mL. 40 mg/0.4mL is almost the only used and efficient types and took 40% market share. By application, Hospital is the largest consumer group, with market share of 63%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Enoxaparin Sodium market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Sanofi
Teva
Techdow (Hepalink)
Fresenius Kabi
Rovi
Amphastar
Nanjing King-friend
Sandoz
Apotex
Hangzhou Jiuyuan Gene Engineering
Cipla
Taj Pharma
Chengdu Baiyu Pharmaceutical
Suzhou Erye Pharmaceutical
Changzhou Qianhong Bio-pharma
Hebei Changshan Biochemical Pharmaceutical
Beijing SL Pharmaceutical
Huadong Medicine
Bharat Serums
INTAS
LUPIN
Troikaa Pharmaceuticals
Aristopharma
Fosun Pharma
SciencePharma
PISA
Segment by Type
20 mg/0.2mL
30 mg/0.3mL
40 mg/0.4mL
60 mg/0.6mL
80 mg/0.8mL
100 mg/1mL
120 mg/0.8mL
150 mg/1mL
300mg/3mL
Hospital
Clinic
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Enoxaparin Sodium market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Enoxaparin Sodium, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Enoxaparin Sodium industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Enoxaparin Sodium in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Enoxaparin Sodium introduction, etc. Enoxaparin Sodium Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Enoxaparin Sodium market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Enoxaparin Sodium report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Enoxaparin Sodium market is projected to reach US$ 5354.7 million in 2034, increasing from US$ 3044.5 million in 2022, with the CAGR of 8.3% during the period of 2024 to 2034. Demand from Hospital and Clinic are the major drivers for the industry.
Europe is the largest market of Enoxaparin Sodium, with about 60% market share, followed by North America with about 17% market share. Currently, there are many players in this market.Sanofi, Teva, Techdow (Hepalink), Fresenius Kabi, Rovi, Amphastar, Nanjing King-friend, Sandoz and some others are playing important roles in Enoxaparin sodium injection industry. Sanofi, Teva, Techdow (Hepalink), Fresenius Kabi and Rovi are the top 5 players of Enoxaparin Sodium, with about 85% market shares.
There are nine different dosage form of Enoxaparin Sodium. The market can be segmented into 20 mg/0.2mL, 30 mg/0.3mL, 40 mg/0.4mL, 60 mg/0.6mL, 80 mg/0.8mL, 100 mg/1mL, 120 mg/0.8mL, 150 mg/1mL, 300mg/3mL. 40 mg/0.4mL is almost the only used and efficient types and took 40% market share. By application, Hospital is the largest consumer group, with market share of 63%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Enoxaparin Sodium market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Sanofi
Teva
Techdow (Hepalink)
Fresenius Kabi
Rovi
Amphastar
Nanjing King-friend
Sandoz
Apotex
Hangzhou Jiuyuan Gene Engineering
Cipla
Taj Pharma
Chengdu Baiyu Pharmaceutical
Suzhou Erye Pharmaceutical
Changzhou Qianhong Bio-pharma
Hebei Changshan Biochemical Pharmaceutical
Beijing SL Pharmaceutical
Huadong Medicine
Bharat Serums
INTAS
LUPIN
Troikaa Pharmaceuticals
Aristopharma
Fosun Pharma
SciencePharma
PISA
Segment by Type
20 mg/0.2mL
30 mg/0.3mL
40 mg/0.4mL
60 mg/0.6mL
80 mg/0.8mL
100 mg/1mL
120 mg/0.8mL
150 mg/1mL
300mg/3mL
Segment by Application
Hospital
Clinic
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Enoxaparin Sodium market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Enoxaparin Sodium, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Enoxaparin Sodium industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Enoxaparin Sodium in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Enoxaparin Sodium introduction, etc. Enoxaparin Sodium Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Enoxaparin Sodium market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.